These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
573 related articles for article (PubMed ID: 34359836)
1. YTHDF1 Promotes Cyclin B1 Translation through m Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W Cells; 2021 Jul; 10(7):. PubMed ID: 34359836 [TBL] [Abstract][Full Text] [Related]
2. SAM68 promotes tumorigenesis in lung adenocarcinoma by regulating metabolic conversion via PKM alternative splicing. Zhu S; Chen W; Wang J; Qi L; Pan H; Feng Z; Tian D Theranostics; 2021; 11(7):3359-3375. PubMed ID: 33537092 [No Abstract] [Full Text] [Related]
3. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759 [TBL] [Abstract][Full Text] [Related]
4. Expression and Prognostic Significance of m6A-Related Genes in Lung Adenocarcinoma. Zhang Y; Liu X; Liu L; Li J; Hu Q; Sun R Med Sci Monit; 2020 Feb; 26():e919644. PubMed ID: 32086933 [TBL] [Abstract][Full Text] [Related]
5. KIAA1429 promotes the progression of lung adenocarcinoma by regulating the m6A level of MUC3A. Zhao W; Xie Y Pathol Res Pract; 2021 Jan; 217():153284. PubMed ID: 33249400 [TBL] [Abstract][Full Text] [Related]
6. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis. Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047 [No Abstract] [Full Text] [Related]
7. Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival. Li T; Liu J; Zhou Y; Huang S; Wang D; Chen J; Fu Y; He P Cancer Med; 2024 May; 13(10):e7227. PubMed ID: 38770632 [TBL] [Abstract][Full Text] [Related]
8. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Schabath MB; Welsh EA; Fulp WJ; Chen L; Teer JK; Thompson ZJ; Engel BE; Xie M; Berglund AE; Creelan BC; Antonia SJ; Gray JE; Eschrich SA; Chen DT; Cress WD; Haura EB; Beg AA Oncogene; 2016 Jun; 35(24):3209-16. PubMed ID: 26477306 [TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Bjaanæs MM; Fleischer T; Halvorsen AR; Daunay A; Busato F; Solberg S; Jørgensen L; Kure E; Edvardsen H; Børresen-Dale AL; Brustugun OT; Tost J; Kristensen V; Helland Å Mol Oncol; 2016 Feb; 10(2):330-43. PubMed ID: 26601720 [TBL] [Abstract][Full Text] [Related]
10. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma. Wu C; Rao X; Lin W Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730 [TBL] [Abstract][Full Text] [Related]
11. The essential roles of m Ma L; Xue X; Zhang X; Yu K; Xu X; Tian X; Miao Y; Meng F; Liu X; Guo S; Qiu S; Wang Y; Cui J; Guo W; Li Y; Xia J; Yu Y; Wang J J Exp Clin Cancer Res; 2022 Jan; 41(1):36. PubMed ID: 35078505 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Kim S; Kim J; Jung Y; Jun Y; Jung Y; Lee HY; Keum J; Park BJ; Lee J; Kim J; Lee S; Kim J Mol Cells; 2020 Jul; 43(7):619-631. PubMed ID: 32638704 [TBL] [Abstract][Full Text] [Related]
13. Potential Predictive Value of Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262 [No Abstract] [Full Text] [Related]
14. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis. Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333 [TBL] [Abstract][Full Text] [Related]
15. N Wang A; Zeng Y; Zhang W; Zhao J; Gao L; Li J; Zhu J; Liu Z; Huang JA Cell Mol Biol Lett; 2024 Aug; 29(1):106. PubMed ID: 39095708 [TBL] [Abstract][Full Text] [Related]
16. Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma. Liang Y; Maeda O; Kondo C; Nishida K; Ando Y PLoS One; 2024; 19(7):e0307580. PubMed ID: 39037971 [TBL] [Abstract][Full Text] [Related]
17. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. Fathi Z; Mousavi SAJ; Roudi R; Ghazi F PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458 [TBL] [Abstract][Full Text] [Related]
18. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352 [TBL] [Abstract][Full Text] [Related]
19. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Liu T; Wei Q; Jin J; Luo Q; Liu Y; Yang Y; Cheng C; Li L; Pi J; Si Y; Xiao H; Li L; Rao S; Wang F; Yu J; Yu J; Zou D; Yi P Nucleic Acids Res; 2020 Apr; 48(7):3816-3831. PubMed ID: 31996915 [TBL] [Abstract][Full Text] [Related]
20. Isoform specific gene expression analysis of KRAS in the prognosis of lung adenocarcinoma patients. Yang IS; Kim S BMC Bioinformatics; 2018 Feb; 19(Suppl 1):40. PubMed ID: 29504894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]